NCT05136287View on ClinicalTrials.gov

SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.

CompletedOBSERVATIONAL
Enrollment

140

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

November 15, 2023

Study Completion Date

January 1, 2024

Conditions
Weight LossDiabetes Mellitus, Type 2Quality of LifeSafety Issues
Interventions
DRUG

GLP-1 receptor agonist

Patients are included after GLP1 agonists prescription , at the first dispensation

Trial Locations (11)

Unknown

Centro de Salud de Culleredo, Culleredo

Centro de Salud de Fene, Fene

Centro de Salud de Ribeira, Ribeira

Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela

Centro de Salud de Ribadeo, Ribadeo

Centro de Salud de Vilalba, Vilalba

Centro de Salud de O Carballiño, O Carballiño

Centro de Salud Valmiñor, Nigrán

Centro de Salud de O Ventorrillo, A Coruña

Centro de Salud de San Roque, Lugo

Centro de Salud Virxe Peregrina, Pontevedra

All Listed Sponsors
lead

Jose Seijas Amigo

OTHER